Wow, what was Bob smoking? $18.5 million loss....

Quote
anonymous said:
#CRITICISMISAWESOME.

Criticism is a conversation between AWESOME people who all risk owning and sharing their ideas for the sake of building something GREAT together. Criticism is a powerful and positive tool when everyone in the conversation has some skin in the game. Everyday there are struggles in our personal and professional lives. But the process of remaining true to the mission is where courage is tested and strong values are formed. Happy Friday:)
Click to expand...

Glad you're open to criticism. Here's some constructive criticism, so don't take it personally, lady. That was a crap post. #BullshitBob
 






Let's get back to the core issue here. As a professional sales person, is this company worth working for? So I initially worked in a Fortune 500 pharma company for a couple of years and "graduated" as a Professional Sales Representative. I then spent three years as a Territory Manager at another big company. Then I got married, had a couple of kids. Usual story. Decided to rejoin the professional sales world as a contract rep. Did a couple of stints at InVentiv and ended up here last Fall. Well, it's been a bumpy road. The two products that were introduced us to the world of controlled pain control unfortunately suck, that's covered by others throughout this thread. It looks like we're about 26.4% behind quota to the mid year. There are rumors that it's more or less. I've been thinking of calling it a day however we're like a month from the FDA review meeting, that's August 4. There's talk of planning for a National Sales meeting in the Fall to paunch Arymo. So what do I do? Stick it out for another month of really depressing days or quit? At least my two lovely daughters always put a smile on my face.
 






anonymous said:
Let's get back to the core issue here. As a professional sales person, is this company worth working for? So I initially worked in a Fortune 500 pharma company for a couple of years and "graduated" as a Professional Sales Representative. I then spent three years as a Territory Manager at another big company. Then I got married, had a couple of kids. Usual story. Decided to rejoin the professional sales world as a contract rep. Did a couple of stints at InVentiv and ended up here last Fall. Well, it's been a bumpy road. The two products that were introduced us to the world of controlled pain control unfortunately suck, that's covered by others throughout this thread. It looks like we're about 26.4% behind quota to the mid year. There are rumors that it's more or less. I've been thinking of calling it a day however we're like a month from the FDA review meeting, that's August 4. There's talk of planning for a National Sales meeting in the Fall to paunch Arymo. So what do I do? Stick it out for another month of really depressing days or quit? At least my two lovely daughters always put a smile on my face.
Click to expand...
I get your pain. I'm in the same boat. I'll stick it out for another few months having come this far with these management losers then we'll see if Arymo launches this Fall. In the meantime I've polished up the resume, contacted the recruiters and am scanning LinkedIn. Unlike a couple of years ago there's a lot of hiring going on. Good luck!!
 






anonymous said:
Let's get back to the core issue here. As a professional sales person, is this company worth working for? So I initially worked in a Fortune 500 pharma company for a couple of years and "graduated" as a Professional Sales Representative. I then spent three years as a Territory Manager at another big company. Then I got married, had a couple of kids. Usual story. Decided to rejoin the professional sales world as a contract rep. Did a couple of stints at InVentiv and ended up here last Fall. Well, it's been a bumpy road. The two products that were introduced us to the world of controlled pain control unfortunately suck, that's covered by others throughout this thread. It looks like we're about 26.4% behind quota to the mid year. There are rumors that it's more or less. I've been thinking of calling it a day however we're like a month from the FDA review meeting, that's August 4. There's talk of planning for a National Sales meeting in the Fall to paunch Arymo. So what do I do? Stick it out for another month of really depressing days or quit? At least my two lovely daughters always put a smile on my face.
Click to expand...

I personally believe Oxaydo & Sprix have destroyed any chance you had at building credibility with the docs in your territory, and they will continue to look at any drug Egalet launches as a complete joke.
With that said, I wouldn't flat out quit my job, but start actively pursuing other opportunities. One of the great perks of his job is you can interview with other companies while still being gainfully employed.
 






Radie Robert S, who is President and CEO at Egalet, sold 15,000 shares at $5.01 on July 6, 2016. Following this transaction, the President and CEO owned 249,900 shares meaning that the stake was reduced by 5.66% with the 15,000-share transaction.

Musial Stan, who is Chief Financial Officer at Egalet, sold 13,480 shares at $5.06 on July 6, 2016. Following this transaction, the Chief Financial Officer owned 81,460 shares meaning that the stake was reduced by 14.2% with the 13,480-share transaction.

The average volume for Egalet has been 132,000 shares per day over the past 30 days. Egalet has a market cap of $127.9 million and is part of the health care sector and drugs industry. Shares are down 54.08% year-to-date as of the close of trading on Wednesday.
 






Soooooooooooo your saying there's a CHANCE!!!!

Rats leaving the boat? said:
Radie Robert S, who is President and CEO at Egalet, sold 15,000 shares at $5.01 on July 6, 2016. Following this transaction, the President and CEO owned 249,900 shares meaning that the stake was reduced by 5.66% with the 15,000-share transaction.

Musial Stan, who is Chief Financial Officer at Egalet, sold 13,480 shares at $5.06 on July 6, 2016. Following this transaction, the Chief Financial Officer owned 81,460 shares meaning that the stake was reduced by 14.2% with the 13,480-share transaction.

The average volume for Egalet has been 132,000 shares per day over the past 30 days. Egalet has a market cap of $127.9 million and is part of the health care sector and drugs industry. Shares are down 54.08% year-to-date as of the close of trading on Wednesday.
Click to expand...
 












anonymous said:
I personally believe Oxaydo & Sprix have destroyed any chance you had at building credibility with the docs in your territory, and they will continue to look at any drug Egalet launches as a complete joke.
With that said, I wouldn't flat out quit my job, but start actively pursuing other opportunities. One of the great perks of his job is you can interview with other companies while still being gainfully employed.
Click to expand...

Yes, you're right on.
 












anonymous said:
I personally believe Oxaydo & Sprix have destroyed any chance you had at building credibility with the docs in your territory, and they will continue to look at any drug Egalet launches as a complete joke.
With that said, I wouldn't flat out quit my job, but start actively pursuing other opportunities. One of the great perks of his job is you can interview with other companies while still being gainfully employed.
Click to expand...

Thanks, took your advice. I'm resigning this week. New job with a professional pharma company starts in August. So excited, glad to be out of this mess.
 


















Two new patents! Yay!

"The newly issued patents further strengthen our ability to grow our business with immediate- and extended-release formulations of products using Guardian Technology," said Bob Radie, president and chief executive officer of Egalet.
 






...and our stock dropped 2% on the announcement....however that's Wall St. The FDA review on Aug 4 will be better then we'll be all set for a great launch of Arymo in the Fall. I'm pumped, glad I joined Egalet, no regrets.
 
























So stock is predictably moving up ahead of Aug 4 webcast. Going to be interesting, sales well below plan - Sprix and Oxyado are failing.

What will the FDA say about Arymo? More importantly, what will our docs say/think about it? A repackaged, century old drug, morphine. Where's the innovation in that?
 






anonymous said:
So stock is predictably moving up ahead of Aug 4 webcast. Going to be interesting, sales well below plan - Sprix and Oxyado are failing.

What will the FDA say about Arymo? More importantly, what will our docs say/think about it? A repackaged, century old drug, morphine. Where's the innovation in that?
Click to expand...

Just about sums it up. Morale is so low. Stan will cook the numbers and spin away. Sales suck and since Deanna left, because of her non compete with Shinogi, marketing has been directionless.
 






  • Net Loss: Net loss for the quarter ended June 30, 2016 was $23.8 million, or $0.97 per share, compared to a net loss of $17.1 million, or $1.03 per share, for the quarter ended June 30, 2015.
 






Top Bottom
Back
Quote